October 2024 Newsletter

Materna Medical: Combatting a U.S Maternal Mortality Crisis

GHIF is proud to announce our Special Purpose Vehicle (SPV) to invest in Materna Medical, led by CEO Tracy MacNeal. Materna Medical (Materna) is addressing the US maternal health crisis with an OBGYN medical device, Prep, that has been shown to reduce C-sections, reduce postpartum hemorrhage, and eliminate pelvic floor injuries to new moms.  This data, pending publication, is the basis for a $20M Series B2.  The first close was completed for $6 Million with a second close expected in November 2024. The second close will be used to propel Prep and their other product Milli to the next step.

The value of Materna was identified immediately by our investors who saw them for the trailblazers they are and complimentary to current portfolio company Raydiant Oximetry. As industry leaders, Materna is in the process of creating a whole new product class as categorized by the FDA. Through a 286 person study they have already begun laying the foundation for dominating the market. The results yielded decreases in pelvic floor injuries, c-sections and postpartum hemorrhages, by 100%, 49% and 50% respectively. As Materna continues to grow it hopes to provide expecting mothers a life altering addition to their birthing plan, making hospitals profitable in labor and delivery in the process.

The SPV we are targeting is a $1 million raise that is currently still open for investments. GHIF’s investment in Maternal Medical is another example of our strong commitment to improving maternal health outcomes post our Raydiant Oximetry investment.